CMPX - Compass Therapeutics, Inc.

QQQ $ 452.83 $ 6.97 (1.56 %)

DIA $ 399.31 $ 3.70 (0.94 %)

SPY $ 529.09 $ 6.48 (1.24 %)

TLT $ 92.14 $ 1.24 (1.36 %)

GLD $ 220.89 $ 2.80 (1.28 %)

Previous Close

$ 1.54

Open

$ 1.65

Bid

$ 0.00 x 0

Ask

$ 1.57 x 400

Day's Range

$ 1.55 - $ 1.66

52 Week Range

$ 1.15 - $ 3.62

Volume

684,157

Average Volume

Market Cap

211.89M

Beta (5Y Monthly)

$ 0.68

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-13-2024	03-31-2024	10-Q
2	03-21-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-15-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-01-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	03-18-2022	12-31-2021	10-K
11	11-12-2021	09-30-2021	10-Q
12	08-16-2021	06-30-2021	10-Q
13	04-30-2021	03-31-2021	10-Q
14	03-05-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	06-08-2020	03-31-2020	10-K
18	02-14-2020	12-31-2019	10-Q
19	11-13-2019	09-30-2019	10-Q
20	08-13-2019	06-30-2019	10-Q
21	07-01-2019	03-31-2019	10-K
22	02-14-2019	12-31-2018	10-Q
23	11-14-2018	09-30-2018	10-Q
24	08-14-2018	06-30-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Comp...
05/14/2024 14:50:48

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 ...

Compass Therapeutics Q1 EPS $(0.08) Beats ...
05/13/2024 12:21:43

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of ...

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
05/01/2024 20:31:24

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
04/26/2024 20:31:15

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
04/25/2024 12:06:47

Compass Therapeutics Receives FDA Fast Tra...
04/25/2024 12:01:49

CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical respon...

HC Wainwright & Co. Reiterates Buy on Comp...
04/16/2024 16:20:43

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 ...

Compass Therapeutics Announces First Patie...
04/16/2024 12:17:13

Compass Therapeutics Presents Data Demonst...
04/09/2024 16:01:18

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resista...

Wedbush Reiterates Outperform on Compass T...
03/22/2024 13:58:06

Wedbush analyst Robert Driscoll reiterates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and maintains $8 price target.

HC Wainwright & Co. Maintains Buy on Compa...
03/21/2024 15:15:51

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 p...

Compass Therapeutics Q4 EPS $(0.11) Misses...
03/21/2024 13:01:16

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate o...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
03/13/2024 13:06:03

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 21:31:07

Compass Therapeutics Publishes CTX-8371 Pr...
02/28/2024 13:13:56

12 Health Care Stocks Moving In Tuesday's ...
02/27/2024 21:31:08

12 Health Care Stocks Moving In Wednesday'...
01/17/2024 21:31:08

Compass Therapeutics Provides Corporate Up...
01/05/2024 13:11:41

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF...

Compass Therapeutics Q3 2023 EPS $(0.08) U...
11/09/2023 13:26:48

Recap: Compass Therapeutics Q3 Earnings
11/09/2023 12:45:07